Caption Management’s Tvardi Therapeutics TVRD Stock Holding History

Caption Management’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,700	Closed	-$66.2K	–	2180
2025 Q3	$66.2K	Buy	+1,700	New	+$48.4K	﹤0.01%	1554
2021 Q3	–	Sell	-1,389	Closed	-$713K	–	1853
2021 Q2	$713K	Buy	1,389 +461	+50%	+$292K	0.01%	977
2021 Q1	$725K	Buy	+928	New	+$635K	0.02%	737
2020 Q1	–	Sell	-2,083	Closed	-$1.21M	–	1121
2019 Q4	$1.21M	Buy	+2,083	New	+$1.46M	0.04%	463
2019 Q3	–	Sell	-5,556	Closed	-$4.3M	–	928
2019 Q2	$4.3M	Buy	+5,556	New	+$3.9M	0.22%	139

Other funds holding TVRD

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AFG

American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SAM

Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

DWAM

Duncan Williams Asset Management Memphis, Tennessee $361M AUM 18% 1-Year Est. Return

Caption Management's TVRD Position: Q3 2022 in Review

Caption Management sold out of Tvardi Therapeutics (TVRD) in Q3 2022, closing a stake of 1,164 shares — an estimated $383K sold.

Caption Management first reported a position in TVRD in Q1 2019 and held it in 6 quarters. The position peaked at $2.07M in Q1 2021. 164 funds tracked by Wall St. Rank hold TVRD as of Q3 2022.

Caption Management reported no remaining Tvardi Therapeutics position as of Q3 2022 after selling out during the quarter.
Caption Management sold 1,164 Tvardi Therapeutics shares in Q3 2022, an estimated $383K.
Caption Management first reported a position in Tvardi Therapeutics in Q1 2019 and held it in 6 quarters.
Caption Management's Tvardi Therapeutics position peaked at $2.07M in Q1 2021.
164 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.